ORM-12741

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414634

CAS#: 610782-82-6

Description: ORM-12741 is an alpha-2C adrenergic receptor antagonist.


Chemical Structure

img
ORM-12741
CAS# 610782-82-6

Theoretical Analysis

MedKoo Cat#: 414634
Name: ORM-12741
CAS#: 610782-82-6
Chemical Formula: C18H23NO2
Exact Mass: 285.1729
Molecular Weight: 285.39
Elemental Analysis: C, 75.76; H, 8.12; N, 4.91; O, 11.21

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ORM-12741; ORM12741; ORM 12741

IUPAC/Chemical Name: 2H-Benzofuro(2,3-a)quinolizine, 1,3,4,6,7,12b-hexahydro-1-(methoxymethyl)-1-methyl-, (1S,12bS)-

InChi Key: OCUKPFWNSAAHRP-QZTJIDSGSA-N

InChi Code: InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1

SMILES Code: C[C@]1(COC)CCCN2CCC3=C(OC4=CC=CC=C43)[C@]12[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 285.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Shahid M, Rinne JO, Scheinin M, Virta J, Marjamäki P, Solin O, Arponen E, Sallinen J, Kuokkanen K, Rouru J. Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the α2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Res. 2020 Dec 9;10(1):152. doi: 10.1186/s13550-020-00741-y. PMID: 33296042; PMCID: PMC7726058.

2: Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J. Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimers Dement (N Y). 2016 Dec 8;3(1):1-9. doi: 10.1016/j.trci.2016.11.004. PMID: 29067315; PMCID: PMC5651366.

3: Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28. PMID: 28300462.

4: Herrick AL, Murray AK, Ruck A, Rouru J, Moore TL, Whiteside J, Hakulinen P, Wigley F, Snapir A. A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold- induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford). 2014 May;53(5):948-52. doi: 10.1093/rheumatology/ket421. Epub 2014 Jan 31. PMID: 24489014.

5: Nissinen J, Andrade P, Natunen T, Hiltunen M, Malm T, Kanninen K, Soares JI, Shatillo O, Sallinen J, Ndode-Ekane XE, Pitkänen A. Disease-modifying effect of atipamezole in a model of post-traumatic epilepsy. Epilepsy Res. 2017 Oct;136:18-34. doi: 10.1016/j.eplepsyres.2017.07.005. Epub 2017 Jul 12. PMID: 28753497.

6: Uys MM, Shahid M, Harvey BH. Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective. Front Psychiatry. 2017 Aug 14;8:144. doi: 10.3389/fpsyt.2017.00144. PMID: 28855875; PMCID: PMC5558054.